Alnylam Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. 

CEO
Yvonne L. Greenstreet
CEOYvonne L. Greenstreet
Employees
2,500
Employees2,500
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2002
Founded2002
Employees
2,500
Employees2,500

ALNY Key Statistics

Market cap
21.40B
Market cap21.40B
Price-Earnings ratio
7.98
Price-Earnings ratio7.98
Dividend yield
—
Dividend yield—
Average volume
3.68M
Average volume3.68M
High today
$165.00
High today$165.00
Low today
$162.27
Low today$162.27
Open price
$159.11
Open price$159.11
Volume
130.76K
Volume130.76K
52 Week high
$479.79
52 Week high$479.79
52 Week low
$156.00
52 Week low$156.00

Stock Snapshot

As of today, Alnylam Pharmaceuticals(ALNY) shares are valued at $164.96. The company's market cap stands at 21.4B, with a P/E ratio of 7.98.

As of 2026-11-04, Alnylam Pharmaceuticals(ALNY) stock has fluctuated between $162.27 and $165.00. The current price stands at $164.96, placing the stock +1.7% above today's low and -0.0% off the high.

The Alnylam Pharmaceuticals(ALNY)'s current trading volume is 130.76K, compared to an average daily volume of 3.68M.

In the last year, Alnylam Pharmaceuticals(ALNY) shares hit a 52-week high of $479.79 and a 52-week low of $156.00.

In the last year, Alnylam Pharmaceuticals(ALNY) shares hit a 52-week high of $479.79 and a 52-week low of $156.00.

ALNY News

Simply Wall St 14h
Can Alnylam Pharmaceuticals Justify Its Price After A 62% Fall?

has seen its share price fall sharply over the past year, even as fresh clinical data and earnings headlines keep arriving. This puts the focus squarely on whet...

Can Alnylam Pharmaceuticals Justify Its Price After A 62% Fall?
Seeking Alpha 5d
Alnylam downgraded at Bernstein on TRITON-CM trial design

Bernstein on Friday downgraded Alnylam Pharmaceuticals (ALNY) to Market Perform from Outperform, citing concerns over the design of its TRITON-CM Phase 3 trial...

Alnylam downgraded at Bernstein on TRITON-CM trial design
Zacks 5d
ALNY Stock Down 25% Despite Q3 Earnings Beat on Demand Growth Concerns

Alnylam Pharmaceuticals (ALNY Quick QuoteALNY - Free Report) reported third-quarter 2026 adjusted earnings of $16.26 per share, beating the Zacks Consensu...

ALNY Stock Down 25% Despite Q3 Earnings Beat on Demand Growth Concerns

Analyst ratings

67%

of 33 ratings
Buy
66.7%
Hold
33.3%
Sell
0%

More ALNY News

Simply Wall St 5d
Alnylam Pharmaceuticals Could Be 53% Undervalued As Earnings And Trial Data Impress

Advertisement Why Alnylam Pharmaceuticals Stock Is Back in Focus Alnylam Pharmaceuticals (ALNY) just combined a big earnings surprise with fresh clinical data...

People also own

Based on the portfolios of people who own ALNY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.